Strobel, Benjamin
Klein, Holger
Leparc, Germán
Stierstorfer, Birgit E.
Gantner, Florian
Kreuz, Sebastian
Article History
Received: 13 January 2022
Accepted: 8 July 2022
First Online: 16 July 2022
Competing interests
: All authors are employees of Boehringer Ingelheim Pharma GmbH & Co. KG (BI). BI has filed a patent application containing parts of this work. The application discloses the identification of miRNAs involved in the pathogenesis of fibrosing lung disease and methods for the treatment of PF-ILD by functional modulation of respective miRNAs in PF-ILD patients, in particular IPF patients.